JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Formulation and Pharmacokinetics of Immediate-Release Oral Contraceptives

Naga Satish Gandham[1], Sunitha Kamidi*[2]

[1]*UG Scholar, Department of Pharmaceutical Analysis, Koringa College of Pharmacy, Korangi, Kakinada, Andhra Pradesh, India*
[2]*Assistant Professor, Department of Pharmaceutical Analysis, Koringa College of Pharmacy, Korangi, Kakinada, Andhra Pradesh, India*

Publication history: Received on 9th July 2025; Revised on 18th Aug 2025; Accepted on 25th August 2025

Article DOI: 10.69613/2prmvh74

Abstract: Immediate-release oral contraceptives are of vital importance in modern reversible contraception. These formulations, primarily categorized as combined oral contraceptives (COCs) containing both an estrogen and a progestin, or progestin-only pills (POPs), are engineered for rapid disintegration and subsequent drug absorption. The therapeutic efficacy of these agents is critically dependent on achieving and maintaining plasma hormone concentrations sufficient to inhibit ovulation and induce changes in cervical mucus and the endometrium. This is achieved through clever formulation design, where the selection of pharmaceutical excipients is paramount. Binders, diluents, and lubricants ensure tablet integrity and manufacturability, while solubilizing agents are often required to improve the dissolution of poorly water-soluble hormones like ethinylestradiol and various progestins. The inclusion of superdisintegrants, such as croscarmellose sodium and sodium starch glycolate, is a key strategy to accelerate tablet breakup, thereby facilitating prompt drug release. While offering the benefits of a rapid onset of action and ease of manufacturing, immediate-release dosage forms present significant clinical challenges. The characteristic rapid absorption and elimination profile results in substantial fluctuations in plasma hormone levels, creating a narrow window for dosing. This pharmacokinetic profile makes the therapy highly unforgiving of missed or delayed doses, which remains a primary contributor to contraceptive failure in typical use. This review discusses about the formulation of these essential medicines and compares the advantages and limitations that define their clinical application.

Keywords: Oral Contraceptives; Immediate-Release Formulations; Pharmacokinetics; Superdisintegrants; Patient Adherence.

1. Introduction

Oral contraceptives are among the most widely utilized forms of reversible birth control globally, fundamentally altering the landscape of reproductive health since their introduction. These hormonal preparations function by modulating the hypothalamic-pituitary-ovarian axis to prevent pregnancy [1]. The formulations are broadly classified into two categories: combined oral contraceptives (COCs), which contain both a synthetic estrogen (typically ethinylestradiol) and a progestin, and progestin-only pills (POPs), which contain only a progestin. The vast majority of these products are manufactured as immediate-release (IR) tablets. This dosage form is designed to disintegrate and release the active pharmaceutical ingredient (API) rapidly upon ingestion, allowing for swift absorption from the gastrointestinal tract [2].

The primary goal of an IR oral contraceptive is to ensure that systemic hormone concentrations quickly reach and are maintained above the minimum effective concentration required for therapeutic action, principally the suppression of ovulation. Peak plasma concentrations of the hormonal agents are typically achieved within one to two hours post-administration [3]. This rapid pharmacokinetic profile is crucial not only for routine daily use but also in specific applications such as emergency contraception. Over the decades, the hormonal doses in oral contraceptives have been significantly reduced to improve the safety profile and minimize side effects, making the precision of the drug delivery system even more critical for maintaining efficacy [4]. The World Health Organization recognizes the importance of these medicines by including them on its Model List of Essential Medicines [5].

This paper provides a detailed examination of the scientific and technological principles governing IR oral contraceptive formulations. It analyzes the classification of these drugs, their mechanisms of action, and the formulation strategies employed to achieve the desired rapid-release characteristics. Furthermore, it critically evaluates the clinical advantages and inherent limitations of the IR dosage form, considering factors such as pharmacokinetic variability, patient adherence, and potential drug interactions. The regulatory landscape, including standards for quality control and bioequivalence, is also considered, as it ensures the safety and consistency of these vital therapeutic agents [6, 7, 8].

* Corresponding author: Sunitha Kamidi

2. Classification of Oral Contraceptives

Oral contraceptive drugs are categorized based on their hormonal composition, which in turn dictates their mechanism of action and clinical suitability for different patient populations. The two principal classes, POPs and COCs, both leverage synthetic hormones to prevent conception, but their pharmacological approaches differ significantly.

2.1. Progestin-Only Pills (POPs)

Progestin-only pills, often referred to as "mini-pills," contain a single hormonal agent—a synthetic progestin such as norethindrone, levonorgestrel, or desogestrel [9]. Formulated without estrogen, POPs are a critical option for individuals with contraindications to estrogen, including those who are breastfeeding, have a history of venous thromboembolism, or possess other cardiovascular risk factors [10]. The primary mechanism of contraceptive action for POPs is the thickening of the cervical mucus, which creates a formidable barrier to sperm penetration. While some higher-dose progestin formulations, particularly those containing desogestrel, can consistently suppress ovulation, this effect is not uniform across all POPs [11].

Table 1. Common Hormonal Agents in Immediate-Release Oral Contraceptives

Hormone Class	Agent	Daily Dose Range	Characteristics
Estrogen	Ethinylestradiol	10 - 50 μg	Synthetic estrogen; provides cycle control and suppresses FSH.
Progestin	Levonorgestrel	30 - 150 μg	Second-generation progestin; well-established efficacy and safety.
	Norethindrone	350 - 1000 μg	First-generation progestin; commonly used in both COCs and POPs.
	Desogestrel	75 - 150 μg	Third-generation progestin; highly selective with low androgenic activity.
	Drospirenone	3000 μg (3 mg)	Fourth-generation progestin; analogue of spironolactone with anti-androgenic and anti-mineralocorticoid properties.

The therapeutic window for POPs is notoriously narrow, and their efficacy is highly dependent on strict adherence to the dosing schedule. The short half-life of most progestins necessitates that the pill be taken within the same three-hour window each day. A delay beyond this period can lead to a rapid decline in contraceptive protection [12]. Consequently, the IR dosage form is essential to ensure a rapid onset of action and the maintenance of therapeutic plasma concentrations needed to sustain the effect on cervical mucus.

2.2. Combined Oral Contraceptives (COCs)

Combined oral contraceptives contain both a synthetic estrogen, most commonly ethinylestradiol, and one of a variety of progestins, such as levonorgestrel, norethindrone acetate, or drospirenone. This dual-hormone approach provides a more robust and multi-faceted mechanism of action compared to POPs [13]. The estrogenic component acts primarily to suppress the release of follicle-stimulating hormone (FSH) from the pituitary gland, thereby preventing the development of a dominant ovarian follicle. The progestin component inhibits the mid-cycle surge of luteinizing hormone (LH), which is the direct trigger for ovulation [14].

Table 2. Comparative Overview of POPs and COCs

Parameter	Progestin-Only Pills (POPs)	Combined Oral Contraceptives (COCs)
Hormonal Content	Single synthetic progestin	Synthetic estrogen and a synthetic progestin
Primary Mechanism	Thickening of cervical mucus	Suppression of ovulation
Efficacy (Perfect Use)	~99.5%	>99.7%
Efficacy (Typical Use)	~91%	~93%
Dosing Window	Strict (must be taken within 3 hours)	More flexible (generally within 12-24 hours)
Advantages	Suitable for estrogen-intolerant individuals (e.g., during lactation, smokers >35 years)	High efficacy, excellent cycle control, numerous non-contraceptive benefits
Limitations	Higher risk of contraceptive failure with missed pills; potential for irregular bleeding	Contraindicated in certain medical conditions (e.g., history of VTE, specific migraines)

Beyond this primary effect on ovulation, COCs also induce secondary contraceptive effects, including the thickening of cervical mucus and the induction of endometrial changes that render the uterine lining unreceptive to implantation. The combined action of these mechanisms results in extremely high efficacy, with perfect-use failure rates below 1%. In addition to contraception, COCs

are widely prescribed for their non-contraceptive benefits, which include the regulation of menstrual cycles, alleviation of dysmenorrhea, improvement in acne, and a reduced risk of ovarian and endometrial cancers [15, 16]. COCs are formulated as IR tablets to facilitate rapid and reliable absorption to ensure consistent suppression of the reproductive axis.

3. Advantages and Limitations

The dominance of IR dosage forms in oral contraception is attributable to a specific set of clinical and manufacturing advantages. However, these benefits are accompanied by significant limitations that have important implications for therapeutic outcomes.

3.1. Benefits of Immediate-Release Formulations

The principal advantages of IR oral contraceptives are their rapid onset of action, ease of use for the patient, cost-effective manufacturing, and the quick reversibility of their contraceptive effect.

3.1.1. Rapid Onset of Action

A defining characteristic of IR formulations is the rapid achievement of therapeutic drug concentrations. Following oral administration, a typical IR tablet is designed to disintegrate within 30 minutes, leading to peak plasma concentrations of hormones like ethinylestradiol and levonorgestrel within one to two hours [19]. This swift pharmacokinetic profile is essential for the immediate initiation of hormonal effects, such as the suppression of ovulation and modification of cervical mucus. This rapid action is especially critical when starting a new contraceptive cycle or in the context of emergency contraception, where any delay in absorption could compromise efficacy [20].



Figure 1. Pharmacokinetic & Pharmacodynamics of IR Oral Contraceptives

3.1.2. Patient Adherence and Simplicity

The design of IR tablets promotes patient adherence through its simplicity. These tablets are typically small, easy to swallow, and administered on a straightforward once-daily schedule. This convenience is a significant factor in the long-term use of oral contraceptives [21]. Compared to more complex drug delivery systems, the IR tablet offers a reliable and uncomplicated therapeutic option that is suitable for a diverse range of users and healthcare settings.

3.1.3. Manufacturing and Cost-Effectiveness

The manufacturing processes for IR tablets, such as direct compression or wet granulation, are well-established, highly efficient, and scalable. These standardized techniques keep production costs low, which is a vital factor for public health initiatives and ensures broad accessibility to these essential medicines [22]. Furthermore, the formulation flexibility of IR tablets allows for the development of various low-dose combinations, multiphasic regimens, and generic equivalents without compromising therapeutic standards.

3.1.4. Rapid Return to Fertility

A notable clinical advantage of IR oral contraceptives is the rapid return to fertility upon discontinuation. Because the synthetic hormones are cleared from the body relatively quickly, a woman's normal menstrual cycle and potential for conception typically resume within one to three months [23]. This feature makes IR contraceptives an ideal choice for individuals planning future pregnancies or those who require short-term birth control.

3.2. Challenges of Immediate-Release Formulations

Despite their widespread use, IR formulations have inherent disadvantages, primarily related to their pharmacokinetic profile and the stringent demands they place on the user.

3.2.1. Pharmacokinetic Variability and Hormonal Fluctuations

The rapid absorption and subsequent metabolism of hormones from IR tablets lead to significant peaks and troughs in plasma drug concentrations throughout the dosing interval [24]. Ethinylestradiol and levonorgestrel, for example, reach a peak concentration shortly after ingestion, followed by a relatively rapid decline as they undergo hepatic metabolism and biliary excretion [25]. These fluctuations can:

- Reduce the safety margin for effective ovulation suppression, particularly with modern low-dose formulations.
- Increase the risk of escape ovulation if a dose is missed or delayed.
- Contribute to hormone-related side effects, such as nausea or breast tenderness, which are often associated with peak plasma levels. Maintaining stable, steady-state hormone levels is inherently more challenging with IR formulations compared to sustained-release systems.

3.2.2. Strict Adherence Requirements

The most significant clinical limitation of IR contraceptives is the need for precise and consistent daily administration. Missing a single dose, especially with POPs, can quickly compromise contraceptive efficacy due to the short biological half-life of the progestins [26]. Most POPs must be ingested within a three-hour window each day to maintain their effectiveness. This strict requirement can be challenging for users, and non-adherence is the leading cause of contraceptive failure in typical use, where failure rates are notably higher than those reported in controlled clinical trials [27].

3.2.3. First-Pass Metabolism and Drug Interactions

Orally administered hormones from IR tablets are subject to extensive first-pass metabolism in the gut wall and liver. This metabolic process can reduce the bioavailability of the active drug. Furthermore, this pathway is susceptible to interactions with other medications. Co-administration of enzyme-inducing drugs, such as certain antiepileptics (e.g., phenytoin) or antibiotics (e.g., rifampin), can accelerate the metabolism of contraceptive steroids, potentially lowering hormone levels below the therapeutic threshold [28]. Gastrointestinal disturbances like vomiting or severe diarrhea can also impair drug absorption, increasing the risk of contraceptive failure.

3.2.4. Lack of a Sustained Hormonal Reservoir

Unlike long-acting reversible contraceptives (LARCs) such as hormonal implants or intrauterine systems (IUSs), IR tablets do not provide a sustained reservoir of hormones [29]. LARCs deliver a continuous, low dose of hormone, which minimizes fluctuations and is independent of user adherence. The absence of this built-in buffer makes IR formulations more vulnerable to user error and the resulting risk of unintended pregnancy.

4. Formulation of Immediate-Release Oral Contraceptives

The development of a successful immediate-release oral contraceptive tablet is a complex process that depends on the careful selection of excipients and the optimization of manufacturing techniques. These elements are synergistic, working together to ensure rapid tablet disintegration, complete drug dissolution, and reliable bioavailability. The ultimate goal is to produce a stable, robust, and cost-effective dosage form that delivers the precise hormonal dose consistently.

4.1. Selection of Pharmaceutical Excipients

Excipients are pharmacologically inactive substances that are included in a formulation to serve specific functions. In the context of low-dose hormonal contraceptives, excipients often constitute the bulk of the tablet's mass. Their selection is critical as it directly influences the tablet's physical properties, manufacturing efficiency, and *in-vivo* performance.

4.1.1. Binders

Binders are adhesive agents added to the powder blend to impart the necessary mechanical strength to the tablet, ensuring it can withstand the rigors of manufacturing, packaging, and handling without crumbling. For an IR formulation, the binder must provide cohesion without impeding the tablet's ability to disintegrate rapidly. Polyvinylpyrrolidone (PVP) is a widely used binder due to its excellent adhesive properties and high solubility in aqueous environments, which facilitates quick tablet breakup [30]. Microcrystalline cellulose (MCC) is another common excipient that functions as a dry binder, contributing to tablet hardness and promoting rapid disintegration.

4.1.2. Fillers and Diluents

The amount of active hormonal ingredient in an oral contraceptive tablet is extremely small, often in the microgram range. Fillers or diluents are therefore required to increase the bulk of the formulation to a size that is practical for compression and handling by the patient. Lactose is the most common filler used in oral contraceptive tablets due to its good compressibility, low cost, and compatibility with most APIs [32]. Mannitol is another option, often used in formulations where moisture sensitivity is a concern.

4.1.3. Solubilizing Agents

Many synthetic steroids used in oral contraceptives, including ethinylestradiol and various progestins, exhibit poor aqueous solubility. This characteristic can be a rate-limiting step for drug absorption. To overcome this, solubilizing agents may be incorporated into the formulation. Cyclodextrins, for instance, can form inclusion complexes with hydrophobic drug molecules, effectively increasing their solubility and dissolution rate [33]. Surfactants like polysorbates can also be used to enhance the wetting of the drug particles, thereby promoting faster dissolution.

4.1.4. Lubricants

Lubricants are essential in tablet manufacturing to reduce the friction between the tablet surface and the die wall during the ejection process. This prevents tablets from sticking to the manufacturing equipment and ensures a smooth production cycle. Magnesium stearate is the most ubiquitously used lubricant in the pharmaceutical industry due to its high efficiency at very low concentrations [34].

Table 3. Classification of Excipients in Oral Contraceptive Tablets

Excipient Class	Primary Function	Common Examples
Binders	Provide mechanical strength and tablet integrity.	Polyvinylpyrrolidone (PVP), Microcrystalline Cellulose (MCC)
Fillers / Diluents	Increase the bulk volume to a practical tablet size.	Lactose Monohydrate, Mannitol
Superdisintegrants	Promote rapid tablet breakup in aqueous environments.	Croscarmellose Sodium, Sodium Starch Glycolate, Crospovidone
Solubilizing Agents	Enhance the dissolution of poorly soluble APIs.	Cyclodextrins, Polysorbates (e.g., Tween 80)
Lubricants	Reduce friction during tablet ejection from the die.	Magnesium Stearate, Stearic Acid
Glidants	Improve the flow properties of the powder blend.	Colloidal Silicon Dioxide

4.2. Manufacturing

The method used to manufacture the tablets plays a pivotal role in determining the final product's quality attributes, including content uniformity, hardness, and dissolution profile. Direct compression and granulation are the two primary approaches.

4.2.1. Direct Compression

Direct compression is a streamlined process where the powdered APIs and excipients are blended and then compressed directly into tablets without an intermediate granulation step. This method is highly efficient, cost-effective, and particularly suitable for drugs that are sensitive to heat or moisture, as it avoids the use of liquids and drying steps [36, 37]. Its success, however, is highly

dependent on the physical properties of the formulation components, which must possess good flowability and compressibility [38]. Excipients specifically designed for direct compression, such as spray-dried lactose or MCC, are often required [39].

4.2.2. Granulation Techniques

Granulation is a process of particle size enlargement in which fine powders are agglomerated into larger, free-flowing granules. This is often necessary when the API or excipient blend has poor flow or compression characteristics. Granulation improves dose uniformity, prevents segregation of the components, and enhances the compaction properties of the material.

Table 4. Tablet Manufacturing Techniques

Parameter	Direct Compression	Wet Granulation	Dry Granulation
Process Complexity	Low (simple blend and compress)	High (multi-step: wetting, drying, milling)	Moderate (compaction and milling)
Suitability for APIs	Best for drugs with good flow/compressibility	Suitable for most drugs, including those with poor flow	Best for moisture- or heat-sensitive drugs
Cost & Time	Low cost, rapid production	High cost, time-consuming	Moderate cost and time
Advantage	Efficiency and suitability for sensitive APIs	Produces robust granules with excellent uniformity	Avoids use of liquids and heat
Limitation	Requires specialized excipients; risk of segregation	Unsuitable for heat/moisture sensitive drugs	Can produce more fines; lower tablet hardness

Wet Granulation: This is the most common granulation method. It involves adding a liquid binder solution to the powder mixture to form a wet mass, which is then dried and milled to the desired granule size before being compressed. Wet granulation is highly effective for achieving excellent content uniformity and producing robust tablets [40]. However, the process is multi-stepped, time-consuming, and unsuitable for moisture- or heat-sensitive hormones [41].

Dry Granulation: This technique involves compacting the powder blend using high pressure, either by slugging (forming a large tablet) or roller compaction (passing powders between two rollers). The resulting compacts are then milled into granules. Dry granulation is an ideal alternative for APIs that are sensitive to moisture and heat [42]. The main challenge with this method is that it can produce a higher percentage of fine particles, which may affect flowability and tablet weight uniformity [43].



Figure 2. Tablet Manufacturing Processes

4.3. Superdisintegrants in Promoting Drug Release

For an immediate-release tablet, rapid disintegration is the first and often rate-limiting step to drug dissolution and absorption. Superdisintegrants are a class of excipients specifically designed to accelerate this process dramatically. They are effective at low concentrations and function by absorbing water and swelling or wicking fluid into the tablet core, which generates disruptive forces that break the tablet apart.

Table 5. Mechanisms of Action for Common Superdisintegrants

Mechanism	Description	Example Superdisintegrants
Swelling	The excipient absorbs water and swells rapidly, generating internal pressure that breaks the tablet apart.	Sodium Starch Glycolate, Croscarmellose Sodium
Wicking (Capillary Action)	Pores within the excipient draw water into the tablet core, promoting rapid wetting and weakening of the structure.	Crospovidone, Croscarmellose Sodium
Particle Repulsion	Upon wetting, electrically repulsive forces are generated between particles, causing them to push away from each other.	Believed to be a secondary mechanism in many disintegrants.
Deformation Recovery	Particles deformed during tablet compression return to their normal shape upon wetting, disrupting the tablet matrix.	Starch-based disintegrants

The efficacy of oral contraceptives relies on the swift release of the API. Superdisintegrants ensure that the tablet matrix breaks down quickly upon contact with gastrointestinal fluids, exposing the individual drug particles and maximizing the surface area available for dissolution [47]. Common superdisintegrants include:

- Croscarmellose sodium: A cross-linked derivative of cellulose that swells rapidly in water, exerting a strong disintegrating force [48].
- Sodium starch glycolate: A cross-linked starch derivative that also functions primarily by swelling to a high degree.
- Crospovidone: A cross-linked polymer of N-vinyl-2-pyrrolidone that acts through a combination of swelling and wicking actions.

The mechanism of action involves several processes, including swelling, capillary action (wicking) that draws fluid into the tablet, and potentially particle-particle repulsive forces that also contribute to the breakup of the tablet matrix [49, 50]. The selection of an appropriate superdisintegrant is therefore a critical formulation decision to ensure the desired rapid-release profile is achieved.

5. Conclusion

Immediate-release oral contraceptives remain an indispensable tool in reproductive health, offering an effective, accessible, and reversible method of birth control. Their clinical performance is a direct result of decades of formulation science, from the judicious selection of excipients that ensure stability and rapid dissolution to the optimization of manufacturing processes like direct compression and granulation. The incorporation of superdisintegrants has been particularly crucial in ensuring the prompt bioavailability required for these low-dose hormonal agents. However, the fundamental pharmacokinetic profile of the IR dosage form—characterized by rapid absorption and elimination—presents an enduring clinical challenge. The resulting necessity for strict patient adherence to a daily dosing schedule is the primary factor contributing to the gap between perfect-use and typical-use efficacy.

References

[1] Glasier A. Contraception. In: Berek JS, editor. Berek & Novak's gynecology. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2012. p. 267–85

[2] Kaunitz AM. Oral contraceptives: patterns of use. Obstet Gynecol Clin North Am. 2007;34(4):635– 49.

[3] Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in real-life usage. Int J Women's Health. 2014; 6:201–8.

[4] Burkman R. Oral contraceptives: current status. Clin Obstet Gynecol. 2010;53(4):749–57.

[5] World Health Organization. WHO Model List of Essential Medicines – 22nd List, 2021. Geneva: WHO; 2021.

[6] Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med. 1998;338(16):1128–37.

[7] Shah VP, Tsong Y, Sathe P, Liu JP. *In vitro* dissolution profile comparison—statistics and analysis of the similarity factor, f2. Pharm Res. 1998;15(6):889–96.

[8] Stanczyk FZ. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disord. 2002;3(3):211–24.

[9] Sweetman SC, editor. Martindale: The Complete Drug Reference. 37th ed. London: Pharmaceutical Press; 2011.

[10] Coelingh Bennink HJ, van Gennip FA, Gerrits MG, Egberts JF, Gemzell-Danielsson K, KoppKallner H. Health benefits of combined oral contraceptives–a narrative review. The European Journal of Contraception & Reproductive Health Care. 2024 Mar 3;29(2):40-52.

[11] Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 μg versus> 20 μg estrogen combined oral contraceptives for contraception. Cochrane Database of Systematic Reviews. 2013(8).

[12] Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs & aging. 2004 Nov; 21:865-83.

[13] Burkman RT, Collins JA, Shulman LP, Williams JK. Current perspectives on oral contraceptive use. American journal of obstetrics and gynecology. 2001 Aug 1;185(2):S4-12.

[14] Speroff L, Darney PD. A clinical guide for contraception. Lippincott Williams & Wilkins; 2011.

[15] Raviele KM. 4. Reproductive Health and the Practice of Gynecology. Catholic Witness in Health Care: Practicing Medicine in Truth and Love. 2017 Sep 15:105.

[16] Fraser IS. Non-contraceptive health benefits of intrauterine hormonal systems. Contraception. 2010 Nov 1;82(5):396-403.

[17] Stanczyk FZ, Archer DF. Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations. Contraception. 2014 Apr 1;89(4):242-52.

[18] Wu F, Shah H, Li M, Duan P, Zhao P, Suarez S, Raines K, Zhao Y, Wang M, Lin HP, Duan J. Biopharmaceutics applications of physiologically based pharmacokinetic absorption modeling and simulation in regulatory submissions to the US Food and Drug Administration for new drugs. The AAPS Journal. 2021 Mar; 23:1-4.

[19] Stanczyk FZ, Archer DF. Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations. Contraception. 2014 Apr 1;89(4):242-52.

[20] Bruisten SM, Nilsson-Ihrfelt E, Buhrman M, Ekselius L. TOXBASE. Emerg Med J. 2006 Aug; 23 (8): 614-7.

[21] Dinger J, Do Minh T, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large US cohort comparing progestogen and regimen. Obstetrics & Gynecology. 2011 Jan 1;117(1):33-40.

[22] Martindale C. The complete drug reference. Sweetman SC, editor. London: Pharmaceutical press; 2009 Mar.

[23] Hatcher RA. Contraceptive technology. Ardent Media; 2007.

[24] Stanczyk FZ, Archer DF. Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations. Contraception. 2014 Apr 1;89(4):242-52.

[25] Kuhnz W, Hümpel M, Biere H, Gross D. Influence of repeated oral doses of ethinyloestradiol on the metabolic disposition of [13C2]-ethinyloestradiol in young women. European journal of clinical pharmacology. 1996 May; 50:231-5.

[26] Goldenberg RL, Das AF, Meis PJ. Maternal±fetal medicine. Acta Obstet Gynecol Scand. 2001; 80:120-5.

[27] Trussell J. Contraceptive failure in the UnitedStates. Contraception. 2004 Aug 1;70(2):89-96.

[28] Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clinical pharmacokinetics. 1990 Jun; 18:472-84.

[29] French R, Van Vliet H, Cowan F, Mansour D, Morris S, Hughes D, Robinson A, Proctor T, Summerbell C, Logan S, Helmerhorst F. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy. The Cochrane database of systematic reviews. 2004;2004(3):CD001776.

[30] Kolhe P, Patil S, Chopade P, et al. Design and development of controlled release tablets of antihypertensive drug. Int J Pharm Sci. 2013;5(4):395–398.

[31] Hede R, Goycoolea FM. Disintegrants in tablets. In: Lachman L, Liberman HA, Kanig JL, editors. The Theory and Practice of Industrial Pharmacy. 3rd ed. Philadelphia: Lea & Fibiger; 1986. p. 175–179.

[32] Mehta S, Pawar S, Gangwal S, et al. Solid dosage form: A practical approach to oral drug delivery. In: Jain N, editor. Pharmaceutical Dosage Forms: Tablets. 2nd ed. Vol. 2. New York: Marcel Dekker Inc; 2003. p. 763–789.

[33] Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci. 1996;85(10):1017–1025.

[34] Rowe RC, Sheskey PJ, Weller PJ. Handbook of Pharmaceutical Excipients. 6th ed. London: Pharmaceutical Press; 2009.

[35] Vyas SP, Khar RK. Controlled Drug Delivery: Concepts and Advances. 1st ed. New Delhi: Vallabh Prakashan; 2002

[36] Kamboj S, Mittal A, Kumawat M. Direct Compression: A Novel Approach to Tablet Formulation. J Pharm Bio allied Sci. 2012;4(1):9– 15.

[37] Dwivedi J, Sachan P, Wal P, Kosey S, Khan MM. Progressive journey of phytotomies: preparation, characterization, patents, clinical trials & commercial products. J Res Pharm. 2023 Sep 1;27(5):1687-733.

[38] Iqbal MK, Singh PK, Shuaib M, Iqbal A, Singh M. Recent advances in direct compression technique for pharmaceutical tablet formulation. Int J Pharm Res & Devel. 2014;6(1):49-57.

[39] Basudkar V, Gharat SA, Momin MM, Shringarpure M. A review of anti-aging nano formulations: Recent developments in excipients for nano cosmeceuticals and regulatory guidelines. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2022;39(3).

[40] Parikh DM. Handbook of pharmaceutical granulation technology. Drugs and the pharmaceutical sciences. 2005;81.

[41] Bansal AK, Choi J, Simonelli AP. Granulation Techniques: Wet Granulation. In: Banker GS, Anderson NR, editors. Tablets. Vol. 1. New York: Marcel Dekker; 1986. p. 211–237.

[42] Parikh DM. Handbook of pharmaceutical granulation technology. Drugs and the pharmaceutical sciences. 2005;81.

[43] Almeida-Naranjo CE, Guerrero VH, Villamar Ayala CA. Emerging contaminants and their removal from aqueous media using conventional/non-conventional adsorbents: a glance at the relationship between materials, processes, and technologies. Water. 2023 Apr 21;15(8):1626.

[44] Basciani S, Porcaro G. Counteracting side effects of combined oral contraceptives through the administration of specific micronutrients. European Review for Medical & Pharmacological Sciences. 2022 Jul 1;26(13).

[45] Saha SK, Joshi A, Singh R, Dubey K. Review of industrially recognized polymers and manufacturing processes for amorphous solid dispersion-based formulations. Pharmaceutical Development and Technology. 2023 Aug 9;28(7):678-96.

[46] Okur ME, Karantas ID, Okur NU, Siafaka PI. Hypertension in 2017: Update in treatment and pharmaceutical innovations. Current Pharmaceutical Design. 2017 Dec 1;23(44):6795- 814.

[47] Kalasz H, Antal I. Drug excipients. Current medicinal chemistry. 2006 Sep 1;13(21):2535-63.

[48] Singh VK, Singh U, Mishra A, Chandra D, Sahu R. A Review on Mouth Dissolving Tablet Using Different Super Disintegrant. World J. Pharm. Res. 2014 Jul 13;3(7):755-91.

[49] Lasek an A, Koganti S, et al. Use of disintegrants in tablets: A comprehensive review. Drug Dev Ind Pharm. 2014;40(2):183-191.

[50] Qureshi MS, Zafar F, Ali H, Hameed K, Mallick N, Khan S, Baloch SA. Super disintegrant On Disintegrant And Dissolution: A Review on Influence. The Professional Medical Journal. 2016 Oct 10;23(10):1167-70.